Merck & Co., Inc. with ticker code (MRK) now have 26 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $148.00 and $104.00 suggesting an average analyst share price target price of $134.32. (at the time of writing). Given that the stocks previous close was at $120.51 and the analysts are correct then we can expect a percentage increase in value of 11.5%. The 50 day moving average now sits at $123.22 and the 200 day MA is $110.85. The market cap for the company is 307.77B. The stock price is currently at: $121.52 USD
The potential market cap would be $343,035,284,709 based on the market consensus.
The company has a dividend yield of 2.05%. Other points of data to note are a P/E ratio of 810.13, revenue per share of $23.70 and a 2.64% return on assets.
Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, including biological therapies, vaccines and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services for the prevention, treatment and control of disease in all major livestock and companion animal species.
